Skip to content
Biophytis
LIVE HEALTHIER LONGER
Biophytis
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN

Author Archives: Antoine

OCTOBER 14, 2019

Press ReleasesBy Antoine14 October 2019

Biophytis to attend the European Large & MidCap Event in Paris. Read the Press Release[

OCTOBER 4, 2019

Press ReleasesBy Antoine4 October 2019

Biophytis Opens 22nd Clinical Site in the SARA-INT Phase 2b Trial of Sarconeos (BIO101) for the Treatment of Sarcopenia. Read the Press Release

OCTOBER 2, 2019

Press ReleasesBy Antoine2 October 2019

Biophytis to Present Four Posters at the 24th Annual Congress of the World Muscle Society (WMS) in Copenhagen, Denmark. Read the Press Release

SEPTEMBER 26, 2019

Press ReleasesBy Antoine26 September 2019

Biophytis to Present at the 15th International Congress of the European Geriatric Medicine Society in Krakow, Poland. Read the Press Release

SEPTEMBER 19, 2019

Press ReleasesBy Antoine19 September 2019

Biophytis to Present at 15th International Pharma Licensing Symposium in Paris. Read the Press Release

AUGUST 23, 2019

Press ReleasesBy Antoine23 August 2019

Biophytis has signed €24m bond funding from Negma to continue the development of its drug candidates to treat neuromuscular diseases. Read the Press Release

AUGUST 8, 2019

Press ReleasesBy Antoine8 August 2019

Shareholders Aprove All Resolutions of the Extraordinary General Meeting held on August 8, 2019. Read the Press Release

JULY 25, 2019

Press ReleasesBy Antoine25 July 2019

Biophytis Withdraws Registration Statement for Global Offering. Read the Press Release

JULY 12, 2019

Press ReleasesBy Antoine12 July 2019

Biophytis Announces Filing of Amendment to Registration Statement for Global Offering. Read the Press Release

JULY 8, 2019

Press ReleasesBy Antoine9 July 2019

Biophytis Announces the Launch of its Public Offering on Nasdaq. Read the Press Release

←1
234567891011121314151617181920
…2122232425…
262728293031323334
35→
© Biophytis 2006-2025 - Mentions Légales
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
Footer Colonne 1 - Anglais
Go to Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok